Stroke is the second leading cause of death and a major cause of disability in the world. The current generation of thrombolytic agents, such as tissue-type plasminogen activator (tPA), only benefit a limited number of the potential patients with ischemic stroke, and the development of improved therapies for the treatment of stroke depends upon understanding the unique characteristics of the cerebrovasculature. The limited benefit of tPA may be due in part to unique activities that tPA has in the brain beyond its well established role as a fibrinolytic protease. In particular, animal studies have indicated that tPA interacts with at least two different cellular receptors expressed in the brain, and these associations have been linked to both neurotoxicity and altered blood-brain-barrier function. And while there are clear benefits to patents who receive early thrombolytic treatment, these recently described effects of tPA suggest that there are unique challenges for the use of thrombolytic therapy in ischemic stroke. Ideal treatments for ischemic stroke would simultaneously promote the reestablishment of vascular patency, inhibit the development of cerebral edema, reduce the incidence of hemorrhagic transformation, and provide direct neuroprotection. Our previous studies have shown that the natural inhibitor of tPA in the CNS, neuroserpin, appears to act as a neuroprotective agent that can promote significant neuronal survival and cell recovery after stroke. In addition our studies suggest that antagonism within the CNS of the tPA receptor, the LDL Receptor Related Protein (LRP), dramatically reduces blood-brain-barrier dysfunction following stroke. Thus, this proposal will test the hypothesis that during cerebral ischemia tPA, neuroserpin, and LRP function together within the brain to regulate blood-brain-barrier permeability and neuronal survival. We will investigate the mechanisms of this regulation, and test the hypothesis that targeting these interactions will lead to the development of more effective therapies for the treatment of ischemic stroke. We will also evaluate novel treatments for stroke by combining various thrombolytic and neuroprotective agents, and comparing the efficacy of these combined therapies in murine models of stroke.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL054710-13
Application #
7793422
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
13
Fiscal Year
2009
Total Cost
$389,721
Indirect Cost
Name
University of Maryland Baltimore
Department
Type
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Cao, Chunzhang; Zhao, Juanjuan; Doughty, Emily K et al. (2015) Mac-1 Regulates IL-13 Activity in Macrophages by Directly Interacting with IL-13R?1. J Biol Chem 290:21642-51
Fredriksson, Linda; Stevenson, Tamara K; Su, Enming J et al. (2015) Identification of a neurovascular signaling pathway regulating seizures in mice. Ann Clin Transl Neurol 2:722-38
Gabre, J; Chabasse, C; Cao, C et al. (2014) Activated protein C accelerates venous thrombus resolution through heme oxygenase-1 induction. J Thromb Haemost 12:93-102
Strickland, Dudley K; Au, Dianaly T; Cunfer, Patricia et al. (2014) Low-density lipoprotein receptor-related protein-1: role in the regulation of vascular integrity. Arterioscler Thromb Vasc Biol 34:487-98
Craig, Julie; Mikhailenko, Irina; Noyes, Nathaniel et al. (2013) The LDL receptor-related protein 1 (LRP1) regulates the PDGF signaling pathway by binding the protein phosphatase SHP-2 and modulating SHP-2- mediated PDGF signaling events. PLoS One 8:e70432
Muratoglu, Selen C; Belgrave, Shani; Hampton, Brian et al. (2013) LRP1 protects the vasculature by regulating levels of connective tissue growth factor and HtrA1. Arterioscler Thromb Vasc Biol 33:2137-46
Yamamoto, Kazuhiro; Troeberg, Linda; Scilabra, Simone D et al. (2013) LRP-1-mediated endocytosis regulates extracellular activity of ADAMTS-5 in articular cartilage. FASEB J 27:511-21
Fredriksson, Linda; Nilsson, Ingrid; Su, Enming J et al. (2012) Platelet-derived growth factor C deficiency in C57BL/6 mice leads to abnormal cerebral vascularization, loss of neuroependymal integrity, and ventricular abnormalities. Am J Pathol 180:1136-44
Sashindranath, Maithili; Sales, Eunice; Daglas, Maria et al. (2012) The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain 135:3251-64
Yakovlev, Sergiy; Mikhailenko, Irina; Cao, Chunzhang et al. (2012) Identification of VLDLR as a novel endothelial cell receptor for fibrin that modulates fibrin-dependent transendothelial migration of leukocytes. Blood 119:637-44

Showing the most recent 10 out of 112 publications